Understanding off-target ADC lung toxicity: why human-relevant models matter
In the first session of our Season 2 ImmuBYTES webinar series, Principal Scientist, Josephine Joel explores one of the biggest challenges in antibody-drug conjugate development: off-target lung toxicity.
Understanding off-target ADC lung toxicity: why human-relevant models matter Read More »